Source: DD News
Context: A new monoclonal antibody named MAM01 has shown strong protective effects against malaria in an early clinical trial by U.S. researchers.
About MAM01 (Monoclonal Antibody Against Malaria):
What it is?
- MAM01 is a novel monoclonal antibody (mAb) engineered to prevent malaria infection by neutralising the Plasmodium falciparum parasite before it enters the bloodstream.
- It represents a passive immunisation strategy, distinct from traditional vaccines that trigger an active immune response.
Developed by:
- Created by the University of Maryland School of Medicine’s Center for Vaccine Development and Global Health (CVD), USA.
Aim:
- Designed to provide immediate and long-lasting protection against malaria, particularly for young children and pregnant women in endemic regions.
- Seeks to overcome the limitations of existing malaria vaccines that require multiple doses and boosters.
Key Features:
- Targets a conserved region of the Plasmodium falciparum circumsporozoite protein (CSP) — a critical molecule that enables the parasite to infect liver cells.
- Single-dose administration offers months-long protection with minimal side effects.
- Phase 1 trial involved 38 malaria-naïve adults aged 18–50 in a randomised, double-blind, placebo-controlled study.
- Provided 100% protection at the highest dose, with no severe adverse reactions reported.
- Demonstrates dose-dependent efficacy, showing higher protection with increasing antibody concentration.
Significance:
- A breakthrough approach that could transform malaria prevention, especially in sub-Saharan Africa, where over 600,000 deaths occur annually.
- Contributes to the global health goal of malaria elimination under WHO’s Global Technical Strategy (GTS) 2025–2030.
